The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial

Marieke J J Ermers, Maroeska M Rovers, Job B van Woensel, Jan L L Kimpen, Louis J Bont, RSV Corticosteroid Study Group, M ten Berge-Kuipers, J de Bie, D Blom, R Bruinsma, F Brus, M Colombijn, G van Enk, K van der Ent, R van Gent, M Hoetjer, A van der Kaaden, E van Leer, R de Moor, A Nieuwenhuis, M Pekelharing, C Smeets, E de Vries, A van Wermeskerken, D van der Zwet-Fandri, Marieke J J Ermers, Maroeska M Rovers, Job B van Woensel, Jan L L Kimpen, Louis J Bont, RSV Corticosteroid Study Group, M ten Berge-Kuipers, J de Bie, D Blom, R Bruinsma, F Brus, M Colombijn, G van Enk, K van der Ent, R van Gent, M Hoetjer, A van der Kaaden, E van Leer, R de Moor, A Nieuwenhuis, M Pekelharing, C Smeets, E de Vries, A van Wermeskerken, D van der Zwet-Fandri

Abstract

Objective: To determine whether early initiated anti-inflammatory therapy with prolonged high dose inhaled glucocorticoids influences the occurrence and severity of recurrent wheeze after respiratory syncytial virus related lower respiratory tract infections.

Design: Randomised double blind placebo controlled trial.

Setting: Paediatric departments of 19 Dutch clinical centres.

Participants: 243 previously healthy infants (126 boys, 117 girls) aged less than 13 months and admitted to hospital with respiratory syncytial virus infection.

Interventions: 200 mug extra fine hydrofluoroalkane (HFA) beclometasone dipropionate twice daily or matched placebo administered by a pressurised metered dose inhaler and a spacer during the first three months after hospital admission.

Main outcome measure: The primary outcome was the number of days with wheeze in the year after the three month intervention period.

Results: Of the 243 eligible infants, 119 were randomised to receive beclometasone and 124 to receive placebo. No significant difference was found in the number of days with wheeze between the two groups (total days, 1761/33 568 in the beclometasone group v 2301/36 556 in the placebo group, P=0.31) and the proportion of infants with wheeze did not differ between the groups (61% in the beclometasone group v 62% in the placebo group, P=0.90). In the predefined subgroup of infants who did not need mechanical ventilation (n=221), beclometasone reduced the number of days with wheeze by 32% (relative reduction in total days, 1315/30 405 in the beclometasone group v 2120/33 149 in the placebo group, P=0.046). This reduction was most pronounced during the first six months of the follow-up year after intervention. The proportion of infants with wheeze did not differ between the groups (59% in the beclometasone group v 60% in the placebo group, P=0.89).

Conclusions: Early initiated high dose extra fine HFA beclometasone to infants during the first three months after hospital admission for respiratory syncytial virus infection has no major effect on recurrent wheeze. The general use of such treatment during lower respiratory tract infection with respiratory syncytial virus should not be advocated.

Trial registration: Current Controlled Trials ISRCTN12352714.

Conflict of interest statement

Competing interests: None declared.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787470/bin/ermm594598.f1_default.jpg
Fig 1 Flow of patients through study
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787470/bin/ermm594598.f2_default.jpg
Fig 2 Days with wheeze during observation year in total group of infants (Poisson P=0.31) and in subgroup not needing mechanical ventilation (Poisson P=0.05)

References

    1. Bont L, Steijn M, van Aalderen WM, Brus F, Th Draaisma JM, Diemen-Steenvoorde RA, et al. Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax 2004;59:512-6.
    1. Perez-Yarza EG, Moreno A, Lazaro P, Mejias A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J 2007;26:733-9.
    1. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-5.
    1. Kuehni CE, Davis A, Brooke AM, Silverman M. Are all wheezing disorders in very young (preschool) children increasing in prevalence? Lancet 2001;357:1821-5.
    1. Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 2004;23:414-7.
    1. Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M. The economic impact of preschool asthma and wheeze. Eur Respir J 2003;21:1000-6.
    1. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 200012;343:1064-9.
    1. Reijonen T, Korppi M, Kuikka L, Remes K. Anti-inflammatory therapy reduces wheezing after bronchiolitis. Arch Pediatr Adolesc Med 1996;150:512-7.
    1. Carlsen KH, Leegaard J, Larsen S, Orstavik I. Nebulised beclomethasone dipropionate in recurrent obstructive episodes after acute bronchiolitis. Arch Dis Child 1988;63:1428-33.
    1. Kajosaari M, Syvanen P, Forars M, Juntunen-Backman K. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma. Pediatr Allergy Immunol 2000;11:198-202.
    1. Chauliac ES, Silverman M, Zwahlen M, Strippoli MP, Brooke AM, Kuehni AC. The therapy of pre-school wheeze: appropriate and fair? Pediatr Pulmonol 2006;41:829-38.
    1. Kimpen JL, Schaad UB. Treatment of respiratory syncytial virus bronchiolitis: 1995 poll of members of the European Society for Paediatric Infectious Diseases. Pediatr Infect Dis J 1997;16:479-81.
    1. Plint AC, Johnson DW, Wiebe N, Bulloch B, Pusic M, Joubert G, et al. Practice variation among pediatric emergency departments in the treatment of bronchiolitis. Acad Emerg Med 2004;11:353-60.
    1. Cahill P, Finan E, Loftus BG. Management of bronchiolitis: current practices in Ireland. Ir Med J 2002. Jun;95(6):167-9.
    1. Barben J, Hammer J. Current management of acute bronchiolitis in Switzerland. Swiss Med Wkly 2003;133:9-15.
    1. Blom D, Ermers M, Bont L, van Aalderen WM, van Woensel JB. Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. Cochrane Database Syst Rev 2007;(1):CD004881.
    1. Janssens HM, de Jongste JC, Hop WC, Tiddens HA. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model. Chest 2003;123:2083-8.
    1. Kamps AW, van Ewijk B, Roorda RJ, Brand PL. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr Pulmonol 2000;29:39-42.
    1. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WMC, Brus F, Draaisma JT, et al. Monocyte IL-10 production during respiratory syncytial virus bronchiolitis is associated with recurrent wheezing in a one-year follow-up study. Am J Respir Crit Care Med 2000;161:1518-23.
    1. Bunge EM, Essink-Bot ML, Kobussen MP, Suijlekom-Smit LW, Moll HA, Raat H. Reliability and validity of health status measurement by the TAPQOL. Arch Dis Child 2005;90:351-8.
    1. Arets HG, Brackel HJ, van der Ent CK. Applicability of interrupter resistance measurements using the MicroRint in daily practice. Respir Med 2003;97:366-74.
    1. Burney PG, Luczynska C, Chinn S, Jarvis D. The European Community Respiratory Health Survey. Eur Respir J 1994;7:954-60.
    1. Rijcken B. Het Europees luchtwegonderzoek Nederland. Tijdschr Soc Gezondheidsz 1992;(70):259-60.
    1. Bont L, van Aalderen WM, Versteegh J, Brus F, Draaisma JT, Pekelharing-Berghuis M, et al. Airflow limitation during respiratory syncytial virus lower respiratory tract infection predicts recurrent wheezing. Pediatr Infect Dis J 2001;20:277-82.
    1. Greenland S, Finkle WD. A critical look at methods for handling missing covariates in epidemiologic regression analyses. Am J Epidemiol 1995;142:1255-64.
    1. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
    1. Ermers MJ, Hoebee B, Hodemaekers HM, Kimman TG, Kimpen JL, Bont L. IL-13 genetic polymorphism identifies children with late wheezing after respiratory syncytial virus infection. J Allergy Clin Immunol 2007;119:1086-91.
    1. Bisgaard H. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003;167:379-83.
    1. Bisgaard H, Flores-Nunez A, Goh A, Azimi P, Halkas A, Malice MP, et al. Study of montelukast for the treatment of respiratory symptoms of post-RSV-bronchiolitis in children. Am J Respir Crit Care Med 2008;178:854-60.
    1. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr 1998;157:215-20.
    1. Christakis DA, Cowan CA, Garrison MM, Molteni R, Marcuse E, Zerr DM. Variation in inpatient diagnostic testing and management of bronchiolitis. Pediatrics 2005;115:878-84.
    1. Corneli HM, Zorc JJ, Majahan P, Shaw KN, Holubkov R, Reeves SD, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007;357:331-9.
    1. De Boeck K, Van der Aa N, Van Lierde S, Corbeel L, Eeckels R. Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study. J Pediatr 1997;131:919-21.
    1. Bulow SM, Nir M, Levin E, Friis B, Thomsen LL, Nielsen JE, et al. Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Pediatrics 1999;104:e77.
    1. Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listernick R. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 1996;348:292-5.
    1. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006;354:1998-2005.
    1. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006;354:1985-97.
    1. Bont L, Kimpen JL, Ermers MJ. Inhaled corticosteroids and children. N Engl J Med 2006;355:624-5.
    1. McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000;(2):CD001107.
    1. Richter H, Seddon P. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. J Pediatr 1998;132:849-53.
    1. Fox GF, Everard ML, Marsh MJ, Milner AD. Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing. Arch Dis Child 1999;80:343-7.
    1. Lehtinen P, Ruohola A, Vanto T, Vuorinen T, Ruuskanen O, Jartti T. Prednisolone reduces recurrent wheezing after a first wheezing episode associated with rhinovirus infection or eczema. J Allergy Clin Immunol 2007;119:570-5.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj